1. Scrip
  2. >>Therapy Areas

Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate

 
• By Alaric DeArment

Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.

Bacterias 3D rendering
Osel announced results of a Phase I trial combining its microbiome therapy with BMS's Opdivo • Source: Shutterstock

Using the microbiome in the context of oncology is a relatively new concept, but Osel, Inc. is already looking to move its product candidate into Phase III on the back of data from a kidney cancer study published earlier this week. That will depend on finding sufficient funding or a partner, but the company sees a significant role in enhancing the effects of immuno-oncology and other cancer therapeutics.

Results from an investigator-sponsored, randomized Phase I clinical trial were published in Nature Medicine 28 February showing that 30 patients with metastatic renal cell carcinoma (RCC) who received CBM588, an off-the-shelf product, with Bristol Myers Squibb Company’s PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) had a median progression-free survival (PFS) of 12.7 months, compared with 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.